<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00233532</url>
  </required_header>
  <id_info>
    <org_study_id>CANA-03-003</org_study_id>
    <nct_id>NCT00233532</nct_id>
  </id_info>
  <brief_title>Canadian Study of Trandolapril on Blood Pressure in Hypertensive Patients (TRAIL)</brief_title>
  <acronym>TRAIL</acronym>
  <official_title>A Prospective, Open-Label Study to Evaluate the Effect of an Escalating Dose Regimen of Trandolapril on Blood Pressure in Treatment-Na√Øve and Concurrently Treated Hypertensive Patients (TRAIL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The TRAIL study was conducted to examine the effects of escalating doses of an ACE inhibitor,
      trandolapril, on lowering blood pressure in Stage 1-2 hypertensive patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2004</start_date>
  <primary_completion_date type="Actual">June 2005</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effectiveness of escalating dose regimen of trandolapril in controlling blood pressure</measure>
    <time_frame>14 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in blood pressure, safety.</measure>
    <time_frame>14 and 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BP mmHg incremental and absolute change</measure>
    <time_frame>14 and 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Throughout 26 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">2000</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trandolapril</intervention_name>
    <description>0.5, 1,2,4mg/once daily/ for 26 weeks (If BP was not controlled, dose was escalated to the next higher dosage every 4-5 weeks).</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <other_name>ABT-TARKA</other_name>
    <other_name>trandolapril/verapamil</other_name>
    <other_name>TARKA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Stage 1 or 2 Hypertension

        Exclusion Criteria:

          -  Uncontrolled diabetes

          -  Subject has a hypersensitivity to ACE inhibitor
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Medical Information 1-800-633-9110</last_name>
    <role>Study Director</role>
    <affiliation>Abbott</affiliation>
  </overall_official>
  <verification_date>July 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>October 5, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2005</study_first_posted>
  <last_update_submitted>July 18, 2008</last_update_submitted>
  <last_update_submitted_qc>July 18, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 22, 2008</last_update_posted>
  <responsible_party>
    <name_title>Anita Vanjaka, Clinical Research Manager</name_title>
    <organization>Abbott</organization>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <keyword>Trandolapril</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trandolapril</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

